瘦素和急性肺部疾病
Alice Huertas1, Jahar Bhattacharya2
1Université Paris-Saclay, School of Medicine, DYNAMIC Lab, Le Kremlin-Bicêtre, France.
Comprehensive Physiology
|July 10, 2025
概括
素是一种参与新陈代谢的激素,在肺部健康和急性呼吸困扰综合征 (ARDS) 中起着复杂的作用. 它对肺部免疫和炎症的影响仍在研究中,特别是在肥胖方面.
科学领域:
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
背景情况:
- 瘦素主要来自白色脂肪组织,调节新陈代谢,免疫力和炎症.
- 莱普还作为肺部的细胞因子类激素,通过OBR受体和JAK-STAT3 / PI3K通路调节免疫反应.
- 莱普会影响肺部成熟和膜发育.
研究的目的:
- 探索丁在急性肺部疾病中具有争议的作用,特别是急性呼吸困扰综合征 (ARDS).
- 调查ARDS中的"肥胖悖论",肥胖可能会给予保护.
- 为了澄清瘦素对肺炎的影响及其与代谢障碍的相互作用.
主要方法:
- 审查现有的关于莱普在肺生理学和病理学中的功能的文献.
- 对研究ARDS"肥胖悖论"的研究进行分析.
- 检查冲突的动物模型数据关于丁在急性肺损伤 (ALI) 中的作用.
主要成果:
- 莱普在ARDS中的作用仍在争论中;一些证据表明,与肥胖相关的超莱普血症可能具有保护作用.
- 潜在的保护机制包括免疫调节,增强中性粒细胞招募和改善巨细胞功能.
- 肥胖引起的瘦素耐药性可能会抵消潜在的益处,动物研究显示,瘦素对肺部损伤的影响有矛盾的结果.
结论:
- 莱普在肺炎和ARDS中的确切作用需要进一步阐明.
- 了解瘦素与肥胖等代谢障碍的相互作用,对于开发有针对性的ARDS疗法至关重要.
- 需要进一步的研究来解决相互矛盾的发现,并确定勒在肺部疾病中的治疗潜力.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
489
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
489
Other Pulmonary Disorders
913
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
913
Pulmonary Tuberculosis II
379
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
379
Acute Respiratory Failure-II
374
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
374
Pneumonia II: Pathophysiology
594
The pathophysiology of pneumonia involves the following steps:
594
Pneumonia I: Introduction
342
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
342


